Inspire Medical Systems, Inc. (NYSE:INSP) Shares Acquired by Xponance Inc.

Xponance Inc. boosted its holdings in Inspire Medical Systems, Inc. (NYSE:INSP) by 2.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,824 shares of the company’s stock after purchasing an additional 82 shares during the quarter. Xponance Inc.’s holdings in Inspire Medical Systems were worth $709,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Thrivent Financial for Lutherans boosted its holdings in shares of Inspire Medical Systems by 16.8% in the 4th quarter. Thrivent Financial for Lutherans now owns 129,120 shares of the company’s stock valued at $23,937,000 after buying an additional 18,540 shares in the last quarter. Harbour Investments Inc. lifted its position in Inspire Medical Systems by 101.0% in the fourth quarter. Harbour Investments Inc. now owns 197 shares of the company’s stock valued at $37,000 after acquiring an additional 99 shares during the last quarter. Monimus Capital Management LP acquired a new position in Inspire Medical Systems in the fourth quarter valued at $5,099,000. Commonwealth Equity Services LLC boosted its stake in Inspire Medical Systems by 7.8% in the fourth quarter. Commonwealth Equity Services LLC now owns 7,984 shares of the company’s stock valued at $1,480,000 after acquiring an additional 575 shares in the last quarter. Finally, Swiss National Bank grew its holdings in shares of Inspire Medical Systems by 1.0% during the fourth quarter. Swiss National Bank now owns 58,600 shares of the company’s stock worth $10,863,000 after purchasing an additional 600 shares during the last quarter. 94.91% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Inspire Medical Systems

In related news, CTO John Rondoni sold 583 shares of the firm’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total value of $99,395.67. Following the completion of the transaction, the chief technology officer now directly owns 10,424 shares of the company’s stock, valued at $1,777,187.76. This trade represents a 5.30 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Randy Ban sold 25,584 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $183.50, for a total value of $4,694,664.00. Following the sale, the insider now owns 7,259 shares in the company, valued at approximately $1,332,026.50. The trade was a 77.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 26,225 shares of company stock valued at $4,806,530. 4.10% of the stock is owned by company insiders.

Inspire Medical Systems Stock Up 3.6 %

Shares of NYSE:INSP opened at $170.89 on Tuesday. Inspire Medical Systems, Inc. has a 52 week low of $123.00 and a 52 week high of $257.40. The company has a 50-day moving average price of $180.18 and a 200 day moving average price of $191.19. The company has a market cap of $5.09 billion, a P/E ratio of 98.78, a PEG ratio of 2.86 and a beta of 1.48.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings results on Monday, February 10th. The company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 8.19% and a net margin of 6.67%. Analysts expect that Inspire Medical Systems, Inc. will post 2.16 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on INSP shares. Robert W. Baird dropped their price target on Inspire Medical Systems from $252.00 to $248.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 11th. Truist Financial cut their target price on shares of Inspire Medical Systems from $250.00 to $235.00 and set a “buy” rating on the stock in a report on Tuesday, February 11th. Stifel Nicolaus decreased their price target on shares of Inspire Medical Systems from $200.00 to $190.00 and set a “hold” rating for the company in a research note on Tuesday, January 21st. Piper Sandler dropped their price objective on shares of Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating on the stock in a research note on Monday, February 10th. Finally, KeyCorp reaffirmed an “overweight” rating and issued a $234.00 target price (down from $236.00) on shares of Inspire Medical Systems in a report on Friday, January 24th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $228.82.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.